• Amino-oxyacetic acid, previously shown to cause a reversible loss of hearing sensitivity and a reduction in endocochlear potential, was tried as a papillative in human tinnitus. Because the drug seemed to have a cochlear site of action, patients were selected for the study if their audiograms were indicative of cochlear lesions and if there was a reduction in tinnitus following intravenous lidocaine (lidocaine positive). Ten such patients received either 50 or 75 mg of amino-oxyacetic acid four times a day orally for one week or placebo administered in a random, crossover, double-blind design. Of these ten, three reported subjective lessening of tinnitus. One of those three and two others not reporting subjective lessening of tinnitus showed a substantial improvement in speech discrimination scores while receiving amino-oxyacetic acid but not placebo. One additional patient who did not receive lidocaine also reported a subjective lessening of tinnitus. Four patients who were lidocaine negative showed neither subjective nor objective improvement in tinnitus after treatment with amino-oxyacetic acid.
(Arch Otolaryngol 1985;111:803-805)
Reed HT, Meltzer J, Crews P, Norris CH, Quine DB, Guth PS. Amino-oxyacetic Acid as a Palliative in Tinnitus. Arch Otolaryngol. 1985;111(12):803–805. doi:10.1001/archotol.1985.00800140047008
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.